The Catalan biotech company AB-Biotics has acquired the rights to a patent of a technology developed by Universitat de Barcelona (UB), IDIBAPS, Hospital Clínic de Barcelona and CIBERSAM (Consorcio Centro de Investigación Biomédica en Red de Salud Mental). The patented method allows to predict the high or low risk of a patient treated with antipsychotic drugs developing extrapyramidal symptoms. The patent inventors are Amalia Lafuente Flo, Sergi Mas Herrero and Cristina Magdalena Grau from UB; Patricia Gassò Astorga from IDIBAPS and UB; and, Miguel Bernardo Arroyo from Hospital Clínic, UB and CIBERSAM. The project has been managed from the Fundació Clínic Innovation Department.
Archive for the ‘Hospital Clínic’ Category
Mantle cell lymphoma is a very aggressive and difficult to treat cancer originated in blood cells and lymph nodes. To identify the molecular alterations responsible for this tumor, and facilitate the development of new treatments, a team of scientists led by Dr. Xose S. Puente and Dr. Carlos López-Otín, at University of Oviedo, and Dr. Sílvia Beà and Dr. Elias Campo, at IDIBAPS, Hospital Clínic, University of Barcelona, have sequenced the genomes of over 30 of lymphomas. The result of this work, published today in the prestigious U.S. journal Proceedings of the National Academy of Sciences (PNAS), presents the first comprehensive genomic analysis of this disease. “The study provides insight into causes and evolution of this complex neoplasm and has identified targets for new treatments“, says Dr. Silvia Beà, first author of the study.
The list of 20 most cited articles published in the Journal of Hepatology include 4 documents by IDIBAPS – Hospital Clínic investigators
The Journal of Hepatology is the official journal of the European Association for the Study of the Liver (EASL), and a key resource in the specialty. With each issue this Journal publishes original papers, reviews, case reports and letters to the Editor concerned with clinical and basic research in the field of hepatology. Recently it presented the most cited articles since 2008, and 4 of the 20 selected documents are signed by IDIBAPS – Hospital Clínic of Barcelona investigators. This fact underlines the leading international role of the Hepatology Service at the Hospital Clínic of Barcelona and the IDIBAPS teams at the Liver, digestive system and metabolism Area.
The European Network for Rare and Congenital Anaemias (ENERCA) is a project funded by the European Commission through the Executive Agency for Health and Consumers (EAHC). e-ENERCA is the result of three previous phases (ENERCA 1, 2 and 3) that have been successfully developed during the last decade (2002-2012). During the next three years it will develop modern e-Health tools for a better management and knowledge of rare anaemias. As the previous phases of the project, e-ENERCA is coordinated by Prof. Joan-Lluis Vives Corrons, Head of the Red Cell Pathology Unit at the Hospital Clínic of Barcelona, and it pursues the consolidation of a European Reference Network in rare anaemias and focuses in professionals as well as in patients and their families. Coordinated from IDIBAPS, e-ENERCA joins the efforts of 26 expert centers in rare anaemias from 11 European countries. The Kick-off Meeting of e-ENERCA was held on October 14th in Luxemburg.
Experts to report on advances in the search for the ultimate HIV prevention tool – a vaccine – at AIDS vaccine 2013
More than 500 research studies outlining the latest advances and obstacles in the search for an AIDS vaccine will be presented and debated at AIDS Vaccine 2013, the world’s only scientific meeting dedicated exclusively to HIV vaccine research. The conference, which runs Monday, 7 October through Thursday, 10 October, will bring more than 1,000 of the world’s leading vaccine researchers, funders and policy makers to the International Convention Center in Barcelona, Spain for four days of exchange, debate and direction-setting for the field.
AIDS Vaccine 2013 is organized by the Global HIV Vaccine Enterprise and by this year’s local conference hosts, the HIVACAT Program for HIV Vaccine Research, based in Barcelona. A vaccine that could help to stop the global HIV/AIDS epidemic is one of the most-sought-after goals of modern scientific research, and among the most complex scientific challenges ever undertaken.
Assisted Reproductive Technologies are associated with an increased cardiovascular risk in childhood
Research conducted entirely in Barcelona has discovered that fetuses conceived by assisted reproduction (AR) present changes in their heart and arteries even before their birth. These changes are similar to those in children with diabetes and severe obesity representing a significant increase in cardiovascular risk in adulthood. The great importance of the study published in Circulation is the fact that it means an opportunity to reverse this situation from the beginning of life. The study was directed from Hospital Clínic – IDIBAPS of Barcelona by Drs. Eduard Gratacós and Juan Balasch, and its first authors are Drs. Brenda Valenzuela and Fátima Crispi.